AVEO Oncology (AVEO) discloses CHMP regulatory action may be considered if August 2019 interim OS analysis confirms negative trend
Tweet Send to a Friend
AVEO Oncology (NASDAQ: AVEO) disclosed in an SEC filing:In August 2017, the European Commission granted marketing authorization for tivozanib to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
